ALNA Allena Pharmaceuticals (NASDAQ) pre-market Mar 2026: $0.08, most active pick

ALNA stock opened pre-market with heavy volume and a trade price near USD 0.075. Investors are watching Allena Pharmaceuticals, Inc. (ALNA) on the NASDAQ after a wide intraday range between USD 0.06 and USD 0.1459 and volume of 252,311,606 shares. The biotech remains a small-cap, U.S.-listed Healthcare company focused on oral enzyme therapeutics. Early trading suggests speculative interest; we break down valuation, liquidity, catalysts, and model-based outlook from Meyka AI.

ALNA stock pre-market snapshot

ALNA stock is trading pre-market on the NASDAQ at USD 0.075 with yesterday’s close at USD 0.0727. The session open was USD 0.0641, the day low USD 0.06, and the day high USD 0.1459. Volume is elevated at 252,311,606 shares, which points to outsized interest versus typical thin trading for this ticker.

This price action is in the context of a company in the Biotechnology industry, headquartered in Newton, Massachusetts, with 120 employees and a lead candidate ALLN-346 targeting gout in advanced CKD patients.

Why volume is surging for ALNA stock

High volume often reflects news, speculative flow, or liquidity events. For ALNA stock the surge is consistent with low market capitalization and thin free float, which amplify every trade. The large intraday range shows price sensitivity to order flow.

Active traders should note the elevated volume increases volatility and widens bid-ask spreads. Institutional analyst coverage is sparse, so retail and momentum-driven flows can dominate near-term moves.

Financials and valuation for ALNA stock

Allena reports negative earnings and development-stage metrics. Key figures: EPS -0.64, PE ratio around -0.12, cash per share USD 0.92, and book value per share USD 0.58. The current ratio is 2.11, and debt-to-equity is 0.03, indicating low leverage but continued negative operating cash flow.

The company shows operating cash flow per share -1.41 and free cash flow per share -1.43. Price-to-book sits near 0.13, reflecting a distressed market valuation for a biotech with no approved product. These metrics frame ALNA stock as high risk with potential value if development milestones succeed.

Technical outlook and ALNA stock price targets

Short-term technicals show a volatile range and lack of meaningful moving average data due to sporadic trading history. Traders should use tight risk controls and watch the USD 0.06 support and the USD 0.1459 intraday high for momentum cues.

Price targets for planning: conservative USD 0.05 (implied downside -33.33% vs USD 0.075), base USD 0.10 (implied upside 33.33%), and bullish USD 0.20 (implied upside 166.67%). No formal analyst consensus or published price target exists on mainstream services.

Meyka AI rates ALNA with a score out of 100

Meyka AI rates ALNA with a score of 62.67 out of 100 and assigns a B / HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst coverage, and fundamental trends.

Meyka AI’s grading notes the company has cash coverage and low leverage, but negative earnings and high development risk. These grades are informational and not investment advice.

Risks, catalysts, and trading strategy for ALNA stock

Primary risks for ALNA stock include clinical trial outcomes, regulatory setbacks, and continued cash burn. The absence of recent earnings announcements since 2022 increases uncertainty. Key catalysts would be trial readouts, partnership news, or funding events.

For most-active trading strategies, consider position sizing aligned to high volatility. Hedged options are likely illiquid. Long-term investors must weigh the binary R&D outcomes against current valuation and cash runway.

Final Thoughts

Key takeaways on ALNA stock: Allena Pharmaceuticals trades at USD 0.075 pre-market on NASDAQ with unusually high volume of 252,311,606 shares and a wide intraday range. Financials show negative EPS (-0.64) and negative cash flow per share, but healthy cash per share (USD 0.92) and a current ratio of 2.11. Meyka AI’s model-based view is cautious but constructive: Meyka AI’s forecast model projects USD 0.10 at a 12-month horizon, an implied upside of 33.33% versus the current price of USD 0.075. Forecasts are model-based projections and not guarantees. Traders should treat ALNA stock as a high-volatility, speculative biotech play, manage size, and watch near-term catalysts and cash updates. For more data see the company site and market commentary on related tickers; also view our ALNA page on Meyka for live updates: Meyka ALNA page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.